TKI therapy directed against identified oncogenic drivers of GIST, such as mutated Proto-oncogene c-KIT (KIT) and PDGFRA, has revolutionized the treatment of advanced GIST; however, treatment response and resistance patterns vary based on molecular factors.11 Here, PDGFRA is linked to gastrointestinal stromal tumor.